- Home
- VOXR vs EDIT Comparison
VOXR vs EDIT Comparison
Compare VOXR & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VOXR
- EDIT
- Stock Information
- Founded
- VOXR 2014
- EDIT 2013
- Country
- VOXR United States
- EDIT United States
- Employees
- VOXR N/A
- EDIT N/A
- Industry
- VOXR Precious Metals
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VOXR Basic Materials
- EDIT Health Care
- Exchange
- VOXR Nasdaq
- EDIT Nasdaq
- Market Cap
- VOXR 168.0M
- EDIT 156.5M
- IPO Year
- VOXR N/A
- EDIT 2016
- Fundamental
- Price
- VOXR $3.65
- EDIT $2.18
- Analyst Decision
- VOXR
- EDIT Buy
- Analyst Count
- VOXR 0
- EDIT 13
- Target Price
- VOXR N/A
- EDIT $6.73
- AVG Volume (30 Days)
- VOXR 326.1K
- EDIT 1.9M
- Earning Date
- VOXR 08-06-2025
- EDIT 08-06-2025
- Dividend Yield
- VOXR 1.39%
- EDIT N/A
- EPS Growth
- VOXR N/A
- EDIT N/A
- EPS
- VOXR N/A
- EDIT N/A
- Revenue
- VOXR $10,845,445.00
- EDIT $35,837,000.00
- Revenue This Year
- VOXR $16.51
- EDIT N/A
- Revenue Next Year
- VOXR $4.60
- EDIT N/A
- P/E Ratio
- VOXR N/A
- EDIT N/A
- Revenue Growth
- VOXR N/A
- EDIT N/A
- 52 Week Low
- VOXR $2.21
- EDIT $0.91
- 52 Week High
- VOXR $3.79
- EDIT $6.22
- Technical
- Relative Strength Index (RSI)
- VOXR 58.95
- EDIT 69.70
- Support Level
- VOXR $3.47
- EDIT $1.73
- Resistance Level
- VOXR $3.70
- EDIT $2.23
- Average True Range (ATR)
- VOXR 0.20
- EDIT 0.20
- MACD
- VOXR -0.00
- EDIT 0.04
- Stochastic Oscillator
- VOXR 73.83
- EDIT 85.35
About VOXR Vox Royalty Corp.
Vox Royalty Corp is a returns-focused mining royalty company with a portfolio of royalties and streams spanning eight jurisdictions. It has built intellectual property, a technically focused transactional team, and a sourcing network which has allowed Vox to target the highest returns on royalty acquisitions in the mining royalty sector. The company geographically operates Australia, Nigeria, USA, and Brazil.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.